Advertisement

Advertisement
Immunotherapy
Breast Cancer

Immunotherapy ‘Comes of Age’ in Breast Cancer

Immunotherapeutics in breast cancer will likely not be limited to late-stage triple-negative breast cancer. Earlier lines, combination regimens...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, organizations all over the world are focusing on the health and safety of their...

Issues in Oncology
COVID-19

Mitigating the Spread of COVID-19 and Its Impact on Cancer

On March 11, the World Health Organization (WHO) took the step it had been avoiding for weeks and declared that the spread of the coronavirus...


Advertisement
Colorectal Cancer

ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer

ASCO has released a new guideline for clinicians and policymakers in resource-constrained settings on treating patients...

Head and Neck Cancer

Study Suggests Adjuvant Everolimus May Benefit Patients With Advanced Head and Neck Cancer

The mTOR inhibitoreverolimus, used to treat breast and kidney cancers, may benefit patients with advanced squamous...

Advertisement



Sponsored Content


Colorectal Cancer

Van K. Morris, MD, on Stage II Colon Cancer: Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy

Gastrointestinal Cancer

Surgical Margins and Survival in Trial of Adjuvant Imatinib for Localized GIST

A post hoc observational study from the phase III EORTC 62024 trial of adjuvant imatinib in patients with localized gastrointestinal stromal tumors (GIST) showed that improvement in survival with R0 vs R1 resection was no longer evident when tumor rupture was excluded from the R1 category. The...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Head and Neck Cancer
Pain Management

Gopal K. Bajaj, MD, MBA, on Reducing Opioid Use in Patients With Head and Neck Cancer Undergoing Radiotherapy

COVID-19

Clinical Trials to Evaluate Activity of Biologics, Other Agents Against COVID-19

In an effort to expedite research for agents with potential activity against symptoms associated with the novel coronavirus (COVID-19), the U.S. Food and Drug Administration (FDA) is evaluating and/or has approved a number of randomized clinical trials seeking to determine whether a drug has...

COVID-19

Maintaining Blood Donations During the COVID-19 Pandemic

A major casualty of the coronavirus disease 2019 (COVID-19) pandemic is the dramatic decrease in the number of blood donations across the United States. As more people are urged to shelter-in-place and avoid social contact, the number of cancellations in blood drives has been dramatic. According to ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Prostate Cancer
Immunotherapy

Julie N. Graff, MD, on Castration-Resistant Prostate Cancer: Results From KEYNOTE-199 on Pembrolizumab Plus Enzalutamide

Multiple Myeloma
Immunotherapy

Daratumumab for Relapsed or Refractory Multiple Myeloma: Subcutaneous vs Intravenous Dosing

Findings from the phase III COLUMBA trial have shown that subcutaneous daratumumab is not inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics and had an improved safety profile in patients with relapsed or refractory multiple myeloma. These results were published by...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...